Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma